Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06136585 · ClinicalTrials.gov registry record · Phase 3
Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial
A Phase 3 study of Neuromuscular Blocks, sponsored by The Cleveland Clinic.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 80
- Enrollment target
- 1
- Study location
NCT06136585: Recruiting Phase 3 study of Neuromuscular Blocks, sponsored by The Cleveland Clinic.
NCT06136585 is a Phase 3 study of Neuromuscular Blocks that is actively recruiting participants, run by The Cleveland Clinic. The registered enrollment target is 80 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06136585, a Phase 3 study of Neuromuscular Blocks, is actively recruiting participants, sponsored by The Cleveland Clinic.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators propose a single-center, assessor-Blinded, parallel group randomized trial to compare the efficacy of reversal of rocuronium induced neuromuscular blockade by sugammadex versus neostigmine in patients undergoing Endoscopic retrograde cholangiopancreatography at Cleveland Clinic Fairview Hospital.
Primary Outcome
To assess the time required from reversal of neuromuscular block to discharge readiness in patients randomized to sugammadex or neostigmine.
Conditions Studied
Interventions
- DRUG 2 mg/kg sugammadex
- DRUG 0.07 mg/kg neostigmine
Study Locations (1)
Ohio
- Cleveland Clinic Fairview Hospital - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2024-06-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 3 |
What NCT06136585 shows while recruiting
NCT06136585 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (90% lower).
The record links to 1 condition, with Neuromuscular Blocks appearing as the primary indexed condition, and to 2 interventions - of which 2 mg/kg sugammadex is the first listed.
NCT06136585 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT06136585 about?
NCT06136585 is a clinical study titled "Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial". The investigators propose a single-center, assessor-Blinded, parallel group randomized trial to compare the efficacy of reversal of rocuronium induced neuromuscular blockade by sugammadex versus neostigmine in patients undergoing Endoscopic retrograde cholangiopancreatography at Cleveland Clinic Fai...
What is the current status of trial NCT06136585?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 80 participants. The study started on 2024-06-01. Estimated completion is 2026-12-31.
What conditions does trial NCT06136585 study?
This clinical trial studies the following conditions: Neuromuscular Blocks.
What interventions are being tested in trial NCT06136585?
The interventions under investigation include: 2 mg/kg sugammadex (DRUG), 0.07 mg/kg neostigmine (DRUG).
Who is sponsoring clinical trial NCT06136585?
This trial is sponsored by The Cleveland Clinic, which has 688 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06136585 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06136585's enrollment target sits among peer trials
80 1756th of 2000 higher than 233 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI